Clene (CLNN) Projected to Release Earnings on Thursday

Clene (NASDAQ:CLNN) is projected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Clene to post earnings of ($0.37) per share and revenue of $0.0610 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Clene (NASDAQ:CLNN) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.05). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.05 million. On average, analysts expect Clene to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clene Trading Down 15.3%

CLNN stock opened at $4.37 on Wednesday. The stock has a 50-day moving average price of $5.70 and a two-hundred day moving average price of $5.66. Clene has a 12-month low of $3.50 and a 12-month high of $13.50. The company has a market cap of $55.85 million, a PE ratio of -1.37 and a beta of 0.96.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on CLNN shares. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Clene in a research note on Monday, May 4th. Roth Capital reissued a “buy” rating on shares of Clene in a research report on Thursday, May 14th. Weiss Ratings downgraded shares of Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. Finally, D. Boral Capital reissued a “buy” rating and issued a $23.00 price objective on shares of Clene in a research report on Monday, May 4th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.25.

Institutional Investors Weigh In On Clene

A number of large investors have recently modified their holdings of the stock. PEAK6 LLC purchased a new stake in shares of Clene during the 4th quarter valued at about $294,000. State Street Corp boosted its holdings in Clene by 138.4% in the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after acquiring an additional 17,300 shares during the period. Ensign Peak Advisors Inc grew its position in Clene by 668.6% in the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after acquiring an additional 99,481 shares in the last quarter. SymBiosis Capital Partners LLC purchased a new stake in shares of Clene during the fourth quarter valued at approximately $4,523,000. Finally, Geode Capital Management LLC raised its stake in shares of Clene by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after purchasing an additional 6,090 shares during the period. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).